A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy

Matthew T. Wolf, Sudipto Ganguly, Tony L. Wang, Christopher W. Anderson, Kaitlyn Sadtler, Radhika Narain, Christopher Cherry, Alexis J. Parrillo, Benjamin V. Park, Guannan Wang, Fan Pan, Saraswati Sukumar, Andrew Mark Pardoll, Jennifer Hartt Elisseeff

Research output: Contribution to journalArticle

Abstract

Biomaterials in regenerative medicine are designed to mimic and modulate tissue environments to promote repair. Biologic scaffolds (derived from decellularized tissue extracellular matrix) promote a wound-healing (proregenerative) immune phenotype and are used clinically to treat tissue loss, including in the context of tumor resection. It is unknown whether a biomaterial microenvironment that encourages tissue formation may also promote tumor development. We implanted a urinary bladder matrix (UBM) scaffold, which is used clinically for wound management, with syngeneic cancer cell lines in mice to study how wound-healing immune responses affect tumor formation and sensitivity to immune checkpoint blockade. The UBM scaffold created an immune microenvironment that inhibited B16-F10 melanoma tumor formation in a CD4+ T cell-dependent and macrophage-dependent manner. In-depth immune characterization revealed an activated type 2-like immune response that was distinct from the classical tumor microenvironment, including activated type 2 T helper T cells, a unique macrophage phenotype, eosinophil infiltration, angiogenic factors, and complement. Tumor growth inhibition by PD-1 and PD-L1 checkpoint blockade was potentiated in the UBM scaffold immune microenvironment. Engineering the local tumor microenvironment to promote a type 2 wound-healing immune signature may serve as a therapeutic target to improve immunotherapy efficacy.

Original languageEnglish (US)
Article numberaat7973
JournalScience Translational Medicine
Volume11
Issue number477
DOIs
StatePublished - Jan 30 2019

Fingerprint

Tumor Microenvironment
Immunotherapy
Wound Healing
Neoplasms
Urinary Bladder
Biocompatible Materials
Macrophages
Phenotype
Experimental Melanomas
Regenerative Medicine
Angiogenesis Inducing Agents
Helper-Inducer T-Lymphocytes
Eosinophils
Extracellular Matrix
T-Lymphocytes
Cell Line
Wounds and Injuries
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy. / Wolf, Matthew T.; Ganguly, Sudipto; Wang, Tony L.; Anderson, Christopher W.; Sadtler, Kaitlyn; Narain, Radhika; Cherry, Christopher; Parrillo, Alexis J.; Park, Benjamin V.; Wang, Guannan; Pan, Fan; Sukumar, Saraswati; Pardoll, Andrew Mark; Elisseeff, Jennifer Hartt.

In: Science Translational Medicine, Vol. 11, No. 477, aat7973, 30.01.2019.

Research output: Contribution to journalArticle

Wolf, Matthew T. ; Ganguly, Sudipto ; Wang, Tony L. ; Anderson, Christopher W. ; Sadtler, Kaitlyn ; Narain, Radhika ; Cherry, Christopher ; Parrillo, Alexis J. ; Park, Benjamin V. ; Wang, Guannan ; Pan, Fan ; Sukumar, Saraswati ; Pardoll, Andrew Mark ; Elisseeff, Jennifer Hartt. / A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy. In: Science Translational Medicine. 2019 ; Vol. 11, No. 477.
@article{ae92fdeb7bb448d2909d70811c73d82d,
title = "A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy",
abstract = "Biomaterials in regenerative medicine are designed to mimic and modulate tissue environments to promote repair. Biologic scaffolds (derived from decellularized tissue extracellular matrix) promote a wound-healing (proregenerative) immune phenotype and are used clinically to treat tissue loss, including in the context of tumor resection. It is unknown whether a biomaterial microenvironment that encourages tissue formation may also promote tumor development. We implanted a urinary bladder matrix (UBM) scaffold, which is used clinically for wound management, with syngeneic cancer cell lines in mice to study how wound-healing immune responses affect tumor formation and sensitivity to immune checkpoint blockade. The UBM scaffold created an immune microenvironment that inhibited B16-F10 melanoma tumor formation in a CD4+ T cell-dependent and macrophage-dependent manner. In-depth immune characterization revealed an activated type 2-like immune response that was distinct from the classical tumor microenvironment, including activated type 2 T helper T cells, a unique macrophage phenotype, eosinophil infiltration, angiogenic factors, and complement. Tumor growth inhibition by PD-1 and PD-L1 checkpoint blockade was potentiated in the UBM scaffold immune microenvironment. Engineering the local tumor microenvironment to promote a type 2 wound-healing immune signature may serve as a therapeutic target to improve immunotherapy efficacy.",
author = "Wolf, {Matthew T.} and Sudipto Ganguly and Wang, {Tony L.} and Anderson, {Christopher W.} and Kaitlyn Sadtler and Radhika Narain and Christopher Cherry and Parrillo, {Alexis J.} and Park, {Benjamin V.} and Guannan Wang and Fan Pan and Saraswati Sukumar and Pardoll, {Andrew Mark} and Elisseeff, {Jennifer Hartt}",
year = "2019",
month = "1",
day = "30",
doi = "10.1126/scitranslmed.aat7973",
language = "English (US)",
volume = "11",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "477",

}

TY - JOUR

T1 - A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy

AU - Wolf, Matthew T.

AU - Ganguly, Sudipto

AU - Wang, Tony L.

AU - Anderson, Christopher W.

AU - Sadtler, Kaitlyn

AU - Narain, Radhika

AU - Cherry, Christopher

AU - Parrillo, Alexis J.

AU - Park, Benjamin V.

AU - Wang, Guannan

AU - Pan, Fan

AU - Sukumar, Saraswati

AU - Pardoll, Andrew Mark

AU - Elisseeff, Jennifer Hartt

PY - 2019/1/30

Y1 - 2019/1/30

N2 - Biomaterials in regenerative medicine are designed to mimic and modulate tissue environments to promote repair. Biologic scaffolds (derived from decellularized tissue extracellular matrix) promote a wound-healing (proregenerative) immune phenotype and are used clinically to treat tissue loss, including in the context of tumor resection. It is unknown whether a biomaterial microenvironment that encourages tissue formation may also promote tumor development. We implanted a urinary bladder matrix (UBM) scaffold, which is used clinically for wound management, with syngeneic cancer cell lines in mice to study how wound-healing immune responses affect tumor formation and sensitivity to immune checkpoint blockade. The UBM scaffold created an immune microenvironment that inhibited B16-F10 melanoma tumor formation in a CD4+ T cell-dependent and macrophage-dependent manner. In-depth immune characterization revealed an activated type 2-like immune response that was distinct from the classical tumor microenvironment, including activated type 2 T helper T cells, a unique macrophage phenotype, eosinophil infiltration, angiogenic factors, and complement. Tumor growth inhibition by PD-1 and PD-L1 checkpoint blockade was potentiated in the UBM scaffold immune microenvironment. Engineering the local tumor microenvironment to promote a type 2 wound-healing immune signature may serve as a therapeutic target to improve immunotherapy efficacy.

AB - Biomaterials in regenerative medicine are designed to mimic and modulate tissue environments to promote repair. Biologic scaffolds (derived from decellularized tissue extracellular matrix) promote a wound-healing (proregenerative) immune phenotype and are used clinically to treat tissue loss, including in the context of tumor resection. It is unknown whether a biomaterial microenvironment that encourages tissue formation may also promote tumor development. We implanted a urinary bladder matrix (UBM) scaffold, which is used clinically for wound management, with syngeneic cancer cell lines in mice to study how wound-healing immune responses affect tumor formation and sensitivity to immune checkpoint blockade. The UBM scaffold created an immune microenvironment that inhibited B16-F10 melanoma tumor formation in a CD4+ T cell-dependent and macrophage-dependent manner. In-depth immune characterization revealed an activated type 2-like immune response that was distinct from the classical tumor microenvironment, including activated type 2 T helper T cells, a unique macrophage phenotype, eosinophil infiltration, angiogenic factors, and complement. Tumor growth inhibition by PD-1 and PD-L1 checkpoint blockade was potentiated in the UBM scaffold immune microenvironment. Engineering the local tumor microenvironment to promote a type 2 wound-healing immune signature may serve as a therapeutic target to improve immunotherapy efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85060952293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060952293&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aat7973

DO - 10.1126/scitranslmed.aat7973

M3 - Article

VL - 11

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 477

M1 - aat7973

ER -